Literature DB >> 16785401

Expression of cyclooxygenase and lipoxygenase enzymes in nasal polyps of aspirin-sensitive and aspirin-tolerant patients.

Jonathan M Owens1, Kenneth R Shroyer, Todd T Kingdom.   

Abstract

OBJECTIVE: To evaluate the expression of cyclooxygenase (COX) and lipoxygenase (LO) enzymes in nasal polyp specimens from aspirin-sensitive (AS) and aspirin-tolerant (AT) patients.
DESIGN: Immunohistochemical staining of archived tissue. Subjects Specimens from 26 patients (11 AS and 15 AT) with nasal polyps were analyzed; specimens from 4 patients were used as controls.
INTERVENTIONS: Immunohistochemical techniques were used to evaluate the expression of the enzymes COX-1, COX-2, 5-LO, 12-LO, and 15-LO in nasal polyp tissue specimens from AS and AT patients. The results were compared with those of a control group of patients without a history of nasal polyposis or rhinosinusitis.
RESULTS: Characteristic staining patterns of epithelium and submucosal glands were noted for each enzyme. Statistically significant (P<.05) differences in staining of columnar epithelium were noted for COX-1 (basal cell layer cytoplasm), COX-2 (apical cell layer cytoplasm), and 12-LO (full-thickness cytoplasm and nucleus). Increased 15-LO (full-thickness cytoplasm) expression in columnar epithelium was noted only in the AT group. Significant differences in the staining of submucosal glands were noted for COX-2 (plasma membrane and cytoplasm), 12-LO (cytoplasm), and 15-LO (cytoplasm) between control and AS patients as well as between control and AT patients (P<.05). The only significant difference noted between the AS and AT groups was cytoplasm staining for 5-LO in submucosal glands, which was greater in the AS group. No epithelial staining differences were noted between AT and AS patients.
CONCLUSIONS: There were significant differences in the expression of COX and LO enzymes between patients with nasal polyps and controls, irrespective of aspirin sensitivity. With 1 exception, there were no significant differences between AS and AT groups.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785401     DOI: 10.1001/archotol.132.6.579

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  7 in total

1.  Involvement of mitogen-activated protein kinases and nuclear factor kappa B pathways in signaling COX-2 expression in chronic rhinosinusitis.

Authors:  Zhenlin Wang; Qiuhang Zhang; Yuan Li; Peng Li; Gehua Zhang; Yulu Li
Journal:  Inflamm Res       Date:  2009-03-25       Impact factor: 4.575

2.  Involvement of B2 receptor in bradykinin-induced proliferation and proinflammatory effects in human nasal mucosa-derived fibroblasts isolated from chronic rhinosinusitis patients.

Authors:  Yih-Jeng Tsai; Sheng-Po Hao; Chih-Li Chen; Brian J Lin; Wen-Bin Wu
Journal:  PLoS One       Date:  2015-05-13       Impact factor: 3.240

3.  Release of cyclooxygenase-2 and lipoxin A4 from blood leukocytes in aspirin-exacerbated respiratory disease.

Authors:  Ajnacska Rozsasi; Akos Heinemann; Tilman Keck
Journal:  Allergy Rhinol (Providence)       Date:  2016-01-01

4.  C-590T Promoter Polymorphism of the Interleukin (IL)-4 Gene Is Associated with an Increased usceptibility to Nasal Polyposis.

Authors:  Mojgan Mohammadi; Shahriar Dabiri; Hamid Reza Mollaei; Samira Rezaee Jouzdani; Maryam Amizadeh; Jamshid Esmailzadeh; Mohammad Reza Baneshi; Aliasghar Arabi Mianroodi
Journal:  Rep Biochem Mol Biol       Date:  2019-01

Review 5.  Cyclooxygenases and the pathogenesis of chronic rhinosinusitis and nasal polyposis.

Authors:  Josep M Guilemany; Jordi Roca-Ferrer; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2008-05       Impact factor: 4.919

6.  Differential expression of tumor necrosis factor α, interleukin 1β, nuclear factor κB in nasal mucosa among chronic rhinosinusitis patients with and without polyps.

Authors:  Danuta Plewka; Alicja Grzanka; Elzbieta Drzewiecka; Andrzej Plewka; Maciej Misiołek; Grażyna Lisowska; Beata Rostkowska-Nadolska; Radoslaw Gawlik
Journal:  Postepy Dermatol Alergol       Date:  2017-05-29       Impact factor: 1.837

7.  Expression of COX-1, COX-2, 5-LOX and CysLT 2 in nasal polyps and bronchial tissue of patients with aspirin exacerbated airway disease.

Authors:  Monique Vorsprach; Christoph Arens; Stephan Knipping; Dörte Jechorek; Sabine Stegemann-Koniszewski; Eva Lücke; Jens Schreiber
Journal:  Allergy Asthma Clin Immunol       Date:  2019-12-26       Impact factor: 3.406

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.